Clinical Trials Browser

Phase 2/3 × Terminated × Sorafenib × Clear all

NCT02220088 2019-01-11

The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial

Phase 2/3 Terminated

Gastrointestinal

Carcinoma, Hepatocellular